Neurometabolite changes in response to antidepressant medication: A systematic review of 1H-MRS findings

• Published in: NeuroImage clinical Vol. 40; p. 103517
• Main Authors: Boucherie, Daphne E., Reneman, Liesbeth, Ruhé, Henricus G., Schrantee, Anouk
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.01.2023; Elsevier
• Subjects: (es)ketamine; 1H-MRS; GABA; Glutamate; Major Depressive Disorder; Radiology; Review; SNRI; SSRI; SSRI; 1H-MRS; (es)ketamine; SNRI; GABA; Glutamate; Major Depressive Disorder; glutamate
• ISSN: 2213-1582; 2213-1582
• DOI: 10.1016/j.nicl.2023.103517

•SSRIs and SNRIs do not consistently affect Glu/GABA systems in 1H-MRS studies.•Amidst null findings, we find some evidence that (es)ketamine increases ACC Glu.•Standardization of study-, and acquisition protocols for 1H-MRS is essential. Selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), and (es)ketamine are used to treat major depressive disorder (MDD). These different types of medication may involve common neural pathways related to glutamatergic and GABAergic neurotransmitter systems, both of which have been implicated in MDD pathology. We conducted a systematic review of pharmacological proton Magnetic Resonance Spectroscopy (1H-MRS) studies in healthy volunteers and individuals with MDD to explore the potential impact of these medications on glutamatergic and GABAergic systems. We searched PubMed, Web of Science and Embase and included randomized controlled trials or cohort studies, which assessed the effects of SSRIs, SNRIs, or (es)ketamine on glutamate, glutamine, Glx or GABA using single-voxel 1H-MRS or Magnetic Resonance Spectroscopic Imaging (MRSI). Additionally, studies were included when they used a field strength > 1.5 T, and when a comparison of metabolite levels between antidepressant treatment and placebo or baseline with post-medication metabolite levels was done. We excluded animal studies, duplicate publications, or articles with 1H-MRS data already described in another included article. Twenty-nine studies were included in this review. Fifteen studies investigated the effect of administration or treatment with SSRIs or SNRIs, and fourteen studies investigated the effect of (es)ketamine on glutamatergic and GABAergic metabolite levels. Studies on SSRIs and SNRIs were highly variable, generally underpowered, and yielded no consistent findings across brain regions or specific populations. Although studies on (es)ketamine were also highly variable, some demonstrated an increase in glutamate levels in the anterior cingulate cortex in a time-dependent manner after administration. Our findings highlight the need for standardized study and acquisition protocols. Additionally, measuring metabolites dynamically over time or combining 1H-MRS with whole brain functional imaging techniques could provide valuable insights into the effects of these medications on glutamate and GABAergic neurometabolism.